{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=G-CSF+plus+Plerixafor", "query": { "intervention": "G-CSF plus Plerixafor" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 62, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=G-CSF+plus+Plerixafor&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T23:20:12.073Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00479115", "title": "Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fanconi Anemia" ], "interventions": [ { "name": "AMD3100", "type": "DRUG" }, { "name": "AmCell CliniMACs", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 1, "start_date": "2007-05", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2020-10-30", "last_synced_at": "2026-09-16T23:20:12.073Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00479115" }, { "nct_id": "NCT05088356", "title": "Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Allogeneic Hematopoietic Cell Transplantation (HCT)", "Advanced Hematologic Malignancies", "Acute Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndromes", "Myeloproliferative Disorders" ], "interventions": [ { "name": "Purified regulatory T-cells (Treg) plus CD34+ HSPC", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "CliniMACS CD34 Reagent System", "type": "DEVICE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Mycophenolate Mofetil (MMF)", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 66, "start_date": "2021-09-07", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-09-16T23:20:12.073Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05088356" }, { "nct_id": "NCT00822770", "title": "Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stem Cell Transplantation", "Leukemia" ], "interventions": [ { "name": "Plerixafor", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Allogeneic blood stem cell transplant", "type": "PROCEDURE" }, { "name": "ATG (Thymoglobulin)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 47, "start_date": "2009-01", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-09-16T23:20:12.073Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00822770" }, { "nct_id": "NCT07605416", "title": "Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Leukemia" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Daratumumab and Recombinant Human Hyaluronidase", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant Granulocyte Colony-Stimulating Factor", "type": "BIOLOGICAL" }, { "name": "Stem Cell Isolation", "type": "PROCEDURE" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "Transthoracic Echocardiography Test", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 74, "start_date": "2027-04-20", "completion_date": "2032-11-06", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-16T23:20:12.073Z", "location_count": 2, "location_summary": "Buffalo, New York • Salt Lake City, Utah", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07605416" }, { "nct_id": "NCT00476294", "title": "Long-Term Follow Up Study for AMD3100 Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myeloma" ], "interventions": [ { "name": "Telephone Questionnaire", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "78 Years", "sex": "ALL", "summary": "18 Years to 78 Years" }, "enrollment_count": 7, "start_date": "2006-10", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2012-07-11", "last_synced_at": "2026-09-16T23:20:12.073Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00476294" }, { "nct_id": "NCT06414889", "title": "Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "RUNX1 Familial Platelet Disorder" ], "interventions": [ { "name": "G-CSF (filgrastim or biosimilar)", "type": "DRUG" }, { "name": "Apheresis", "type": "PROCEDURE" }, { "name": "Plerixafor", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 4, "start_date": "2024-05-20", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-09-16T23:20:12.073Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06414889" }, { "nct_id": "NCT00998049", "title": "Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Refractory Multiple Myeloma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma" ], "interventions": [ { "name": "plerixafor", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2009-12", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2015-05-14", "last_synced_at": "2026-09-16T23:20:12.073Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00998049" }, { "nct_id": "NCT00396331", "title": "AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autologous Stem Cell Transplantation" ], "interventions": [ { "name": "G-CSF plus plerixafor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "78 Years", "sex": "ALL", "summary": "18 Years to 78 Years" }, "enrollment_count": 100, "start_date": "2005-10", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2014-03-13", "last_synced_at": "2026-09-16T23:20:12.073Z", "location_count": 8, "location_summary": "Duarte, California • Tampa, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00396331" }, { "nct_id": "NCT01746173", "title": "CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Stem Cell Collection", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Stem Cell Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 5, "start_date": "2013-07", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2023-01-30", "last_synced_at": "2026-09-16T23:20:12.073Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01746173" }, { "nct_id": "NCT00082329", "title": "G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "AMD 3100 (Mozobil plerixafor)", "type": "DRUG" }, { "name": "Granulocyte colony-stimulating factor (G-CSF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 9, "start_date": "2004-06-18", "completion_date": "2012-10-25", "has_results": true, "last_update_posted_date": "2021-07-22", "last_synced_at": "2026-09-16T23:20:12.073Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082329" } ] }